Bristol Myers Squibb earnings estimates differ before Q3 release

Higher revenue is expected, but earnings face a year-over-year decline

Bristol Myers Squibb is expected to report third-quarter 2026 results before the market opens on October 29, according to recent previews. The available estimates point to higher revenue than a year earlier but lower earnings per share, although the reported figures vary by source. Management’s outlook will remain central to interpreting the results after the release.

Defense World reported analyst expectations of $12.74 billion in revenue and $1.10 in quarterly earnings per share. Zacks cited consensus estimates of $12.56 billion in revenue and $1.28 in earnings per share, describing a 2.8% year-over-year revenue increase and a 21.5% year-over-year EPS decline. These are pre-release estimates, not reported results, and the difference between them means the exact expected figures remain uncertain.

Estimates point to a more demanding earnings comparison

Zacks said the consensus quarterly EPS estimate had been revised 0.65% lower over the previous 30 days. Its analysis also placed the company’s Most Accurate Estimate below the consensus estimate, producing an Earnings ESP of -15.06%. Zacks cautioned that this reading does not conclusively predict an earnings miss and that the company’s management commentary would be important in assessing the result.

The prior quarter provides context for the comparison, but it is not evidence of third-quarter performance. Defense World reported that Bristol Myers Squibb previously posted $2.04 in earnings per share on $12.97 billion in revenue for the quarter ended July 30, 2026, with revenue up 5.7% from the prior-year quarter.

The next test is the scheduled results release

The company’s earnings overview page was reported to list a conference call for October 29, 2026, at 8:00 a.m. ET. The pre-release reports also referenced fiscal 2026 EPS guidance of $6.750 to $7.000. That guidance remains a company target in the reporting and should not be treated as realized full-year performance.

The main verifiable milestones are the scheduled October 29 results release and management discussion. Investors will be able to compare reported revenue, EPS and management commentary with the differing external estimates; the reports do not establish actual results or broader industry-demand outcomes from this earnings event.